USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
French venture capital firm Sofinnova Partners has announced the closing of a $200 million fund, spearheaded by partners Edward Kliphuis and Simon Turner. 27 October 2023
Sandoz, the generic and biosimilar medicines business of Swiss pharma giant Novartis that was fully spun out on October 4, announced the issuance of two highly successful inaugural CHF bonds with gross proceeds of 750 million francs ($843 million). 27 October 2023
Norway’s clinical-stage biopharmaceutical company Nykode Therapeutics today announced that its private placement has been successfully placed, raising around 505 million Norwegian kroner (~$45 million) in gross proceeds through the allocation of 29,549,400 new shares at a subscription price of 17.10 kroner per share. 25 October 2023
French biotech Abivax has completed an initial public offering (IPO), listing on the Nasdaq global market with 20,325,500 new ordinary shares being issued. 25 October 2023
American critical care specialist Citius Pharma is to list its oncology subsidiary on the Nasdaq exchange, via merger with a special purpose acquisition company (SPAC). 25 October 2023
San Francisco, USA-based biotech start-up Aiolos Bio has today emerged out of stealth, backed by an oversubscribed $245 million Series A investment. 24 October 2023
Seven vaccine research proposals have been chosen for funding, the latest development in a partnership between the Bill and Melinda Gates Foundation and the National Natural Science Foundation of China (NSFC). 24 October 2023
New Jersey, USA-based PTC Therapeutics has announced an agreement with Royalty Pharma to acquire additional royalties on Evrysdi (risdiplam) for $1 billion upfront. 20 October 2023
US antiviral-focused biotech Assembly Biosciences saw its share price rocket nearly 95% to $1.42, on news of a research collaboration with Gilead Sciences. 17 October 2023
Swedish company Egetis Therapeutics has raised around $16 million in a private share placement led by US healthcare investor Frazier Life Sciences. 11 October 2023
Danish biotech MinervaX, a privately held firm working on a novel, prophylactic vaccine against Group B Streptococcus (GBS), has raised $57 million from a range of new and existing sources of finance. 11 October 2023
With the aim of advancing its fibrosis-focused pipeline, Belgian biotech Agomab Therapeutics today announced the closing of a $100 million (94.9 million euros) Series C financing. 11 October 2023
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
Swiss biotech LimmaTech Biologics has announced the closing of a $37 million Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. 9 October 2023
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news